I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| extravillous trophoblast | 3 studies | 39% ± 11% |
Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| extravillous trophoblast | 3 studies | 39% ± 11% |
Insufficient scRNA-seq data for expression of ERVH48-1 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 98% | 56.15 | 240 / 245 | 72% | 14.52 | 363 / 502 |
| bladder | 95% | 11.00 | 20 / 21 | 18% | 8.68 | 91 / 504 |
| thymus | 100% | 50.71 | 651 / 653 | 11% | 0.60 | 66 / 605 |
| ovary | 94% | 19.47 | 169 / 180 | 11% | 0.21 | 49 / 430 |
| lung | 93% | 15.65 | 537 / 578 | 10% | 3.55 | 117 / 1155 |
| pancreas | 98% | 30.07 | 322 / 328 | 3% | 5.46 | 5 / 178 |
| uterus | 91% | 13.63 | 154 / 170 | 8% | 3.05 | 36 / 459 |
| esophagus | 84% | 10.58 | 1207 / 1445 | 13% | 2.41 | 23 / 183 |
| muscle | 93% | 13.95 | 743 / 803 | 0% | 0 | 0 / 0 |
| intestine | 88% | 12.21 | 847 / 966 | 4% | 0.09 | 23 / 527 |
| stomach | 86% | 12.48 | 307 / 359 | 5% | 0.14 | 14 / 286 |
| brain | 88% | 20.17 | 2326 / 2642 | 2% | 0.08 | 11 / 705 |
| breast | 85% | 15.22 | 391 / 459 | 3% | 0.30 | 38 / 1118 |
| skin | 82% | 15.65 | 1492 / 1809 | 1% | 0.01 | 3 / 472 |
| heart | 82% | 9.98 | 707 / 861 | 0% | 0 | 0 / 0 |
| spleen | 78% | 8.85 | 187 / 241 | 0% | 0 | 0 / 0 |
| kidney | 76% | 7.64 | 68 / 89 | 1% | 0.05 | 10 / 901 |
| adipose | 76% | 8.10 | 917 / 1204 | 0% | 0 | 0 / 0 |
| liver | 70% | 8.44 | 158 / 226 | 1% | 0.41 | 6 / 406 |
| adrenal gland | 70% | 6.20 | 180 / 258 | 0% | 0 | 0 / 230 |
| blood vessel | 63% | 6.33 | 840 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 47% | 4.14 | 432 / 929 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 9% | 0.32 | 4 / 45 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_0006949 | Biological process | syncytium formation |
| GO_0005615 | Cellular component | extracellular space |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005515 | Molecular function | protein binding |
| Gene name | ERVH48-1 |
| Protein name | Suppressyn (Endogenous retrovirus group 48 member 1) (NDUFV3 antisense RNA 1) (endogenous retrovirus group Fb member 1) |
| Synonyms | NDUFV3-AS1 HERV-Fb1 C21orf105 |
| Description | FUNCTION: May play a role in trophoblasts syncytialization, the spontaneous fusion of their plasma membranes, an essential process in placental development. May negatively regulate cell-cell fusion by interacting with SLC1A5, the probable receptor on the cell surface of the fusogenic syncytin-1/ERVW-1. . |
| Accessions | ENST00000447535.2 M5A8F1 |
